The Post-Doctoral Fellow with the Hohl Research Group in the UBC Department of Emergency Medicine will conduct drug safety and effectiveness evaluation of treatments used for opioid poisoning in emergency departments using data derived from the Canadian Emergency Department Research Network. The incumbent may also have the opportunity to participate in real-world drug safety and surveillance research using new adverse drug event data being generated by a technological intervention designed to improve clinical communication of patients’ adverse drug events.
The successful applicant will join the Canadian Emergency Department Research Network (CEDRN) coordinating centre for a newly launched research network in Emergency Medicine. This network will seek, as one of its first priorities, to harmonize data collection on treatments and harm reduction strategies used in Canadian emergency departments in 9 provinces for patients presenting with opioid-related harms. This new clinical dataset will be among the first to capture in-hospital treatments and services which are not available through Canadian administrative datasets. The incumbent will have the primary responsibility to co-design and lead analyses of these data for research, quality improvement and surveillance purposes. The incumbent will apply appropriate methods to aid in the creation of a learning health system around opioid-related emergency care in BC and nationally.
The successful applicant will also participate in research opportunities through a thriving adverse drug event research group with a long history of work on this topic. The research group has developed a novel software application called ActionADE that supports the documentation and communication of adverse drug events to providers in other health sectors. The app also supports new federal adverse drug reaction reporting requirements. They will lead studies using ActionADE data generated as a by-product of safer clinical care to help develop a new approach for post-market drug safety surveillance.